Technical update from Aptamer Group – Dr David Bunka shares the latest data & innovations. 6pm BST today. Register: turnerpope.com/register/

ICYMI: Aptamer Group extends contract with a top 5 pharma partner. bit.ly/4lvKSXN

The latest news on progression of the multiple licensing opportunities for our enzyme modulating Optimers, and commercial validation from top five pharmaceutical partner. Learn more: londonstockexchange.com/news-article/A… #APTA

Today we have launched our new biomarker discovery service. Delivering validated, drug-development-ready biomarkers with in months, not years, this new fee-for-service offering creates an additional revenue stream in US$62.4bn global market. polaris.brighterir.com/public/aptamer… #APTA

Discover the markers that matter. Our new Optimer® biomarker discovery service enables high-specificity, functional biomarker identification. We're redefining what’s possible in biomarker discovery. 🔗 aptamergroup.com/biomarker-disc…

We're pleased to announce the signing of a new therapeutic deal with Invizius, to develop Optimers as next generation complement targeting therapies. polaris.brighterir.com/public/aptamer… #APTA

Great coverage of our latest partnership with Invizius from BioPharm Intl. biopharminternational.com/view/what-the-… #APTA

Extracting meaningful biomarkers from complex proteomic datasets is complicated and time-consuming 🔬⏳ Cut the complexity and find actionable biomarkers 🎯 precisely matched to the disease context, target tissue, and therapeutic mechanism with Optimer. aptamergroup.com/biomarker-disc…

Our CSO is in Xiamen, China, for CIFIT at the invitation of the Foreign, Commonwealth & Development Office. A great time connecting with UK delegates, Chinese pharma and biotech, and exploring new opportunities together. Thanks to our hosts for the warm welcome.

Have you seen? Aptamer Group and Invizius are collaborating to elevate H-Guard technology with Optimer binders, aiming for precision and stability in immune-modulating therapies. #ICYMI, read the story below! #Innovation #Biotech #Immunotherapy hubs.li/Q03HBWyJ0

We’re heading to Discovery on Target 2025 📍 Boston, Sept 22–25! Find us at Booth #412 🧬 🧑‍🔬 Meet Zeesharn Farook to learn how our Optimer platform helps scientists: 🎯 hit new targets 🔬 build better assays 💊 develop new therapies 📅 Book a meeting: calendly.com/zeesharn-faroo…

We have signed a new contract with 山 to develop Optimers for rapid Cryptosporidium detection in water. londonstockexchange.com/news-article/A… A key step toward real-time, next-gen pathogen monitoring. #APTA

Inspiring week in China for our CSO, David Bunka: CIFIT in Xiamen + visits to Wuxi, Hefei, Nanjing & Shanghai. 🤝 From meeting pharma & biotech leaders to exploring collaborations, the conversations sparked exciting future possibilities. 🙏 Thanks to our hosts & the FCDO!

The Aptamer Group team is heading to two leading events this September! We’re excited to connect, collaborate, and share how we’re driving innovation in drug discovery and biologics. Come find us!

Uncover disease-defining biomarkers 🔬 with our biomarker discovery service. Our phenotype-first approach 🔍 saves years ⏳ by focusing on markers that work in practice, not just in theory 💭. 📖 Case study: staging oesophageal cancer 👉 aptamergroup.com/new-biomarkers…

At #DiscoveryOnTarget in Boston? 👋 Meet Zeesharn Farook (Booth 412) from Aptamer Group to see how Optimer® binders can unlock tough drug targets & new biomarkers. Sadly the flashy stand didn't make it this year, but we still have great science! 🔬 #Biomarkers #DrugDiscovery

Aptamer Group will be at the ShareSoc Growth Company Seminar in Leeds on October 8th, 2025. CEO, Arron, and CFO, Andrew Rapson, will be presenting on the Company's latest progress on the Optimer platform. polaris.brighterir.com/public/aptamer… #APTA #irchat

Can we stop Alzheimer’s before symptoms appear? With Neuro-Bio Ltd , we’re developing non-invasive, cost-effective early tests using our Optimers that are smaller, more stable & more sensitive than antibodies. Read more: selectscience.net/article/new-la…

We’ve had some fantastic conversations so far and are all set for Day 2 at Festival of Biologics 2025 in Basel. Come by booth 268 to meet Dhara Savsani. She’s looking forward to sharing insights, exchanging ideas, and exploring the latest in biologics with you.

Hear what our customers are experiencing with Optimer technology. ⚡ Superior performance from day one 🧬 Outperforming traditional antibodies Ready to experience the Optimer advantage in your research? Get in touch to learn more.